An article published in Cardiovascular Drugs and Therapy in 2005 about the Prediction of Muscular Risk in Observational conditions (PRIMO) study reported different rates of SAMS with fluvastatin 40 mg (5 percent), pravastatin 40 mg (11 percent) and simvastatin 40 to 80 mg (18 percent).